Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) rose 2.8% during trading on Tuesday . The stock traded as high as $12.21 and last traded at $12.17, with a volume of 145,093 shares traded. The stock had previously closed at $11.84.

SCMP has been the topic of several recent research reports. Zacks Investment Research lowered shares of Sucampo Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 22nd. Roth Capital reiterated a “buy” rating on shares of Sucampo Pharmaceuticals in a research report on Tuesday, July 12th. Maxim Group restated a “buy” rating on shares of Sucampo Pharmaceuticals in a report on Monday, July 11th. WallachBeth Capital upgraded shares of Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 target price on the stock in a report on Thursday, May 5th. Finally, Jefferies Group reduced their target price on shares of Sucampo Pharmaceuticals from $16.00 to $14.00 and set a “hold” rating on the stock in a report on Thursday, August 4th. Five investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $19.67.

The company has a market capitalization of $524.42 million and a P/E ratio of 42.98. The company’s 50-day moving average price is $11.38 and its 200-day moving average price is $11.59.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $0.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.01. The firm had revenue of $52 million for the quarter, compared to analyst estimates of $48.33 million. During the same period in the previous year, the firm earned $0.21 earnings per share. Sucampo Pharmaceuticals’s revenue was up 49.1% on a year-over-year basis. On average, analysts forecast that Sucampo Pharmaceuticals Inc. will post $1.02 earnings per share for the current year.

An institutional investor recently raised its position in Sucampo Pharmaceuticals stock. Systematic Financial Management LP boosted its position in Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) by 18.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 101,745 shares of the biopharmaceutical company’s stock after buying an additional 15,590 shares during the period. Systematic Financial Management LP owned about 0.23% of Sucampo Pharmaceuticals worth $1,759,000 at the end of the most recent reporting period.

Sucampo Pharmaceuticals, Inc is a global biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic, and oncology-based inflammatory disorders. It generates revenue from product royalties, development milestone payments, product sales and clinical development activities.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.